Vivo Capital, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Vivo Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $20,788 - $37,327	-4,166 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$5.12 - $8.19 $2.38 Million - $3.81 Million	-465,422 Reduced 99.11%	4,166 $22,000
Q3 2021 Nov 15, 2021	SELL	$6.68 - $9.1 $8.83 Million - $12 Million	-1,321,669 Reduced 73.78%	469,588 $3.14 Million
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $8.8 Million - $26.3 Million	1,791,257 New	1,791,257 $12.2 Million
Q3 2019 Nov 13, 2019	SELL	$9.59 - $12.0 $17.2 Million - $21.5 Million	-1,791,257 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$10.5 - $14.15 $43,743 - $58,948	4,166 Added 0.23%	1,791,257 $25 Million
Q3 2017 Nov 13, 2017	BUY	$7.7 - $11.55 $13.8 Million - $20.6 Million	1,787,091	1,787,091 $19.7 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.